KR102230628B1 - 보르티옥세틴 제조 방법 - Google Patents

보르티옥세틴 제조 방법 Download PDF

Info

Publication number
KR102230628B1
KR102230628B1 KR1020157021985A KR20157021985A KR102230628B1 KR 102230628 B1 KR102230628 B1 KR 102230628B1 KR 1020157021985 A KR1020157021985 A KR 1020157021985A KR 20157021985 A KR20157021985 A KR 20157021985A KR 102230628 B1 KR102230628 B1 KR 102230628B1
Authority
KR
South Korea
Prior art keywords
formula
compound
piperazine
equivalents
vortioxetine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157021985A
Other languages
English (en)
Korean (ko)
Other versions
KR20150118146A (ko
Inventor
토마스 룰란
킴 라쎄 크리스텐센
Original Assignee
하. 룬드벡 아크티에셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하. 룬드벡 아크티에셀스카브 filed Critical 하. 룬드벡 아크티에셀스카브
Publication of KR20150118146A publication Critical patent/KR20150118146A/ko
Application granted granted Critical
Publication of KR102230628B1 publication Critical patent/KR102230628B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02Iron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020157021985A 2013-02-22 2014-02-20 보르티옥세틴 제조 방법 Active KR102230628B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201300104 2013-02-22
DKPA201300104 2013-02-22
PCT/EP2014/053313 WO2014128207A1 (en) 2013-02-22 2014-02-20 Vortioxetine manufacturing process

Publications (2)

Publication Number Publication Date
KR20150118146A KR20150118146A (ko) 2015-10-21
KR102230628B1 true KR102230628B1 (ko) 2021-03-22

Family

ID=59215387

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157021985A Active KR102230628B1 (ko) 2013-02-22 2014-02-20 보르티옥세틴 제조 방법

Country Status (37)

Country Link
US (1) US9353073B2 (enExample)
EP (1) EP2958903B1 (enExample)
JP (1) JP6464098B2 (enExample)
KR (1) KR102230628B1 (enExample)
CN (1) CN104995181B (enExample)
AP (1) AP2015008640A0 (enExample)
AU (1) AU2014220735B2 (enExample)
BR (1) BR112015019268B1 (enExample)
CA (1) CA2901821A1 (enExample)
CL (1) CL2015002309A1 (enExample)
CR (1) CR20150423A (enExample)
CY (1) CY1118883T1 (enExample)
DK (1) DK2958903T3 (enExample)
DO (1) DOP2015000187A (enExample)
EA (1) EA027756B1 (enExample)
ES (1) ES2625380T3 (enExample)
GE (1) GEP201706749B (enExample)
HR (1) HRP20170607T1 (enExample)
IL (1) IL240501B (enExample)
LT (1) LT2958903T (enExample)
MA (1) MA38338B1 (enExample)
ME (1) ME02671B (enExample)
MX (1) MX362355B (enExample)
MY (1) MY172337A (enExample)
PE (1) PE20151589A1 (enExample)
PH (1) PH12015501807B1 (enExample)
PL (1) PL2958903T3 (enExample)
PT (1) PT2958903T (enExample)
RS (1) RS55932B1 (enExample)
RU (1) RU2652265C2 (enExample)
SG (1) SG11201506651SA (enExample)
SI (1) SI2958903T1 (enExample)
SM (1) SMT201700238T1 (enExample)
TN (1) TN2015000335A1 (enExample)
UA (1) UA116236C2 (enExample)
WO (1) WO2014128207A1 (enExample)
ZA (1) ZA201506050B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2605652B1 (en) 2010-08-18 2017-11-08 Samumed, LLC Diketones and hydroxyketones as catenin signaling pathway activators
ES2709824T3 (es) 2013-02-22 2019-04-17 Samumed Llc Gamma-dicetonas como activadores de la ruta de señalización Wnt/beta-catenina
DK3206686T3 (da) 2014-08-20 2019-12-16 Samumed Llc Gamma-diketoner til behandling og forebyggelse af ældning af huden og rynker
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
EP3274330A1 (en) 2015-03-26 2018-01-31 Cipla Limited Method for making serotonin reuptake inhibitors
CN106279065A (zh) * 2015-05-12 2017-01-04 北京深蓝海生物医药科技有限公司 一种氢溴酸沃替西汀的精制转晶方法
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
EP3414216B1 (en) * 2016-02-08 2020-10-21 AAA Chemistry ApS Arylation of aliphatic amines
JP2019524682A (ja) 2016-07-01 2019-09-05 ハー・ルンドベック・アクチエゼルスカベット 抗うつ作用の速い発現のためのボルチオキセチン投与計画
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN109912538B (zh) * 2019-01-22 2021-03-12 安徽赛乐普制药有限公司 一种抗抑郁药沃替西汀的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029232A1 (en) 2001-10-04 2003-04-10 H. Lundbeck A/S Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005989A (es) * 2001-12-20 2004-09-27 Lundbeck & Co As H Derivados de ariloxifenilo y arilsulfanilfenilo.
KR20090028712A (ko) * 2006-06-16 2009-03-19 하. 룬트벡 아크티에 셀스카브 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029232A1 (en) 2001-10-04 2003-04-10 H. Lundbeck A/S Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Also Published As

Publication number Publication date
RU2015134407A (ru) 2017-03-28
IL240501B (en) 2018-08-30
IL240501A0 (en) 2015-09-24
EA201591349A1 (ru) 2015-12-30
PE20151589A1 (es) 2015-12-03
PL2958903T3 (pl) 2017-08-31
RU2652265C2 (ru) 2018-04-27
WO2014128207A1 (en) 2014-08-28
SMT201700238T1 (it) 2017-07-18
MX362355B (es) 2019-01-14
HK1216098A1 (en) 2016-10-14
CL2015002309A1 (es) 2016-03-04
CR20150423A (es) 2015-10-20
US20160009670A1 (en) 2016-01-14
ES2625380T3 (es) 2017-07-19
CN104995181B (zh) 2017-03-08
PH12015501807B1 (en) 2019-05-31
MY172337A (en) 2019-11-21
US9353073B2 (en) 2016-05-31
EP2958903A1 (en) 2015-12-30
ME02671B (me) 2017-06-20
JP2016509042A (ja) 2016-03-24
BR112015019268B1 (pt) 2023-01-10
LT2958903T (lt) 2017-08-25
MX2015010656A (es) 2015-12-17
AU2014220735A1 (en) 2015-08-20
DOP2015000187A (es) 2015-11-30
HRP20170607T1 (hr) 2017-06-30
EA027756B1 (ru) 2017-08-31
PT2958903T (pt) 2017-05-26
RS55932B1 (sr) 2017-09-29
AP2015008640A0 (en) 2015-08-31
CN104995181A (zh) 2015-10-21
EP2958903B1 (en) 2017-04-12
DK2958903T3 (en) 2017-05-15
MA38338A1 (fr) 2016-09-30
KR20150118146A (ko) 2015-10-21
TN2015000335A1 (en) 2017-01-03
SI2958903T1 (sl) 2017-09-29
SG11201506651SA (en) 2015-09-29
JP6464098B2 (ja) 2019-02-06
MA38338B1 (fr) 2018-10-31
AU2014220735B2 (en) 2017-06-22
GEP201706749B (en) 2017-10-10
CY1118883T1 (el) 2018-01-10
BR112015019268A2 (pt) 2020-01-28
UA116236C2 (uk) 2018-02-26
ZA201506050B (en) 2017-08-30
CA2901821A1 (en) 2014-08-28
PH12015501807A1 (en) 2015-11-09

Similar Documents

Publication Publication Date Title
KR102230628B1 (ko) 보르티옥세틴 제조 방법
JP6018644B2 (ja) 1−[2−(2,4−ジメチル−フェニルスルファニル)−フェニル]−ピペラジンの製造方法
JP5604424B2 (ja) アポトーシス促進剤abt−263の調製のための方法
JP2016509042A5 (enExample)
CN103124718A (zh) 合成2-取代的-1,4-二苯胺的方法
CA3107270A1 (en) Method for producing tetracyclic compound
CN105348220B (zh) 一种氢溴酸沃替西汀的合成方法
CN104628676A (zh) 一种Vortioxetine的制备方法
KR101744046B1 (ko) 실로도신 합성에 유용한 중간체의 제조방법
TWI382975B (zh) 用於製備1-〔3-〔3-(4-氯苯基)丙氧基〕丙基〕-哌啶之方法
CN104592222A (zh) 抗血小板药物azd6482的制备方法
OA17454A (en) Vortioxetine manufacturing process.
NZ710779A (en) Vortioxetine manufacturing process
JP4587139B2 (ja) アミノアルコキシカルボスチリル誘導体の製造方法。
HK1216098B (en) Vortioxetine manufacturing process
JP6911015B2 (ja) インダンアミン誘導体の製法及び新規の合成中間体
CN109384754B (zh) 一种盐酸决奈达隆的制备方法
JP5439745B2 (ja) ハロゲノメチルペンタフルオロスルファニルベンゼン化合物及びその製造方法
CN119638647A (zh) 制备氧杂环丁烷-2-基甲胺或其盐的方法
WO2012051737A1 (zh) 西那卡塞及其药用盐的制备方法
NZ710779B2 (en) Vortioxetine manufacturing process
JP2007119406A (ja) 4−アセチル−1−ベンジル−4−フェニルピペリジン類の製造法
JP2009114123A (ja) 2−アシル−1−アミノピロール化合物の新規製造法
JP2007070300A (ja) 2,5−ジアミノ−1,4−ベンゾキノン及び2,5−ジアミノ−1,4−ベンゼンジオール、およびその塩の製造方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6